首页> 外文期刊>Diabetes therapy >Patient Satisfaction and Clinical Efficacy of Flash Glucose Monitoring in Patients with Type 1 Diabetes: A Prospective, Single-Center, Single-Arm Study
【24h】

Patient Satisfaction and Clinical Efficacy of Flash Glucose Monitoring in Patients with Type 1 Diabetes: A Prospective, Single-Center, Single-Arm Study

机译:患有1型糖尿病患者闪光葡萄糖监测的患者满意度和临床疗效:展望,单中心,单臂研究

获取原文
           

摘要

IntroductionFrequent self-monitoring of blood glucose (SMBG) is usually required in patients with type 1 diabetes (T1D). However, the fear of self-testing, hygiene, and social obstacles may deter some patients from SMBG. Flash glucose monitoring (FGM), a less-invasive glucose monitoring method, was launched in Japan in September 2017. The aim of this study was to evaluate patient satisfaction and the clinical efficacy of FGM in Japanese patients with T1D.MethodsPatient satisfaction with FGM was assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Diabetes Therapy-Related Quality of Life (DTR-QOL) questionnaire before (baseline) and 4 and 12?weeks after initiating FGM use in 20 Japanese patients with T1D. Clinical parameters related to glucose metabolism, such as glycated hemoglobin (HbA1c) levels, were assessed, and glucose fluctuations were evaluated using the FGM data. Values at 4 and 12 weeks after initiating FGM were compared with baseline data using the Wilcoxon signed-rank test. The mean absolute relative difference (MARD) between glucose values detected using the FGM device and by SMBG was also calculated.ResultsThe DTSQ scores significantly improved 12?weeks after initiating FGM ( P ?0.001). The DTR-QOL scores related to “burden in social activities” and “treatment satisfaction” also significantly improved 12?weeks after initiating FGM ( P =?0.024 and 0.007, respectively). The HbA1c values and the percentage of time within the target glucose range (3.9–7.8?mmol/L) at the 12-week time point also improved, from 58?±?5 (baseline) to 54?±?4 mmol/mol ( P =?0.002) and from 36% (interquartile range [IQR] 25–44.5%) (baseline) to 43% (IQR 39–50%) ( P =?0.016), respectively. The MARD between glucose values detected using FGM and those detected using SMBG was 12.2% throughout the study period.ConclusionsFlash glucose monitoring contributed to improved patient satisfaction and the adjustment of blood glucose levels in patients with T1D.Trial RegistrationUniversity Hospital Medical Information Network Clinical Trials Registry.
机译:1型糖尿病(T1D)的患者通常需要引入血糖(SMBG)的自我监测。然而,害怕自我测试,卫生和社会障碍可能会阻止一些来自SMBG的患者。闪存葡萄糖监测(FGM)是2017年9月在日本推出的缺陷血糖监测方法。本研究的目的是评估患者满意度和FGM在日本T1D患者中的临床疗效。与FGM的性能满意度满意使用糖尿病治疗满意度调查问卷(DTSQ)和糖尿病治疗相关的生活质量(DTR-QOL)问卷(DTR-QOL)调查问卷(DTR-QOL)和4和12日,在20名日本T1D患者中使用2周内使用。评估与葡萄糖代谢相关的临床参数,例如糖化血红蛋白(HBA1C)水平,使用FGM数据评估葡萄糖波动。使用Wilcoxon签名 - 等级测试将启动FGM启动FGM的4和12周的值。还计算了使用FGM器件检测到的葡萄糖值与SMBG的平均绝对相对差异(MARD)。在启动FGM后,DTSQ分数明显改善12?周数(P <0.001)。与“社会活动负担”和“治疗满意度”相关的DTR-QOL分数也显着改善了12?在发起FGM后的12个周(P = 0.024和0.007)。 HBA1c值和目标葡萄糖范围内的时间百分比(3.9-7.8?mmol / l),从58°时间点改善,从58?±5(基线)到54?±4 mmol / mol (P = 0.002)和36%(间条形率[IQR] 25-44.5%)(基线)分别为43%(IQR 39-50%)(P = 0.016)。使用FGM检测到的葡萄糖值与使用SMBG检测到的味道在整个研究期间为12.2%。结论血糖监测,有助于提高患者满意度和T1D的患者血糖水平的调整.T1D.TRIAL讲话医院医疗网络临床试验登记处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号